Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Aug 28, 2025
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025.
Read more at globenewswire.com
